BIOHALE® – Products for the Stabilization of Biologics

BioHale^® is  DFE Pharma´s, high-purity, low-endotoxin product portfolio for the stabilization of biologics. Because stability matters.

BioHale^® Key promises:

• Uncompromised quality
• Security of supply
• Expert support

Uncompromised quality

• BioHale® high purity and low endotoxin excipients facilitate the stabilization of biomolecules, thereby reducing the loss of activity and efficacy in your medicines
• Hassle free use and registration of excipients in all markets due to multi-compendial specification
• Ensuring quality by producing in state-of-the-art manufacturing facilities, FDA inspected and in accordance with ICH Q7
• DFE Pharma is a reliable and trusted supplier, known for our high-quality product standards with proven use in global leading Covid-19 vaccines

Specifications compliant with Ph. Eur., USP-NF, JP, ChP monographs

Security of Supply

• Smooth supply of BioHale® excipients. Proven track record of delivering on time in full
• Faster delivery of our BioHale® excipients due to local stocks in Europe, the US and Japan
• BioHale® excipients are independent of raw material variation as the active purification steps ensure first time right quality
• Production capacity available today and tomorrow

Full control of process

Expert support

• We help to speed up your developments and lower pressure on R&D teams by providing the right technical expertise and formulation support
• Swift and accurate qualification and registration due to availability of global and local quality and regulatory support

Excipient Information Package (EIP) and Self- Assessment Questionnaire (SAQ) available on request

Does your company need a predictable supply of high-purity excipients?

See the full brochure on “BIOHALE®” here

(click the picture to download the brochure)

Source: DFE Pharma, brochure “BIOHALE®”

Do you need more information or a sample of DFE Pharma excipients?